Meloxicam Inhibits Hepatocellular Carcinoma Progression and Enhances the Sensitivity of Immunotherapy via the MicroRNA-200/PD-L1 Pathway

Figure 1

Results of screening drugs for anti-HCC ability of 800 compounds approved by the US FDA. (a) Results of screening 800 drugs using CCK8. (b) Results of rescreening several drugs with better efficacy. (c) The effect of meloxicam and sorafenib on the activity of HCC cells at different concentrations. (d) Chemical formula of meloxicam.

(a)

(b)

(c)

(d)